The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer

Immune checkpoint inhibitors have aroused great expectation of tumor eradication. However, the effect of anti-PD-L1 treatment for cervical cancer is unsatisfactory and the underlying antagonist to anti-PD-L1 e...

Source: BMC Immunology - September 3, 2021 Category: Allergy & Immunology Authors: Fengying Xu, Fengying Zhang, Qian Wang, Ying Xu, Shuifang Xu, Caihong Zhang and Lihua Wang Tags: Research Source Type: research